Prelude Therapeutics Incorporat

Historical 13F Holders

Symbol
PRLD
CUSIP
74065P101
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 74065P101 since 12/18/2024, largest first.

Filer % of Class Filed
Orbimed Advisors LLC 13D/A
16.0% 4/23/2026
Event 4/21/2026
Baker Bros. Advisors LP 13D/A
15.5% 4/22/2026
Event 4/20/2026
Vaddi Krishna 13G/A 13.2% 2/13/2026
Event 12/31/2025
RA Capital Management, L.P. 13G
9.9% 4/28/2026
Event 4/21/2026
Incyte Corp 13G 9.9% 11/7/2025
Event 11/3/2025
Soleus Private Equity Fund III, L.P. 13G
5.2% 7/8/2026
Event 4/21/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (1)
James E. Flynn 13G/A
0% 2/13/2025
Event 12/31/2024

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 94 52.1 M $204M
2026 Q2 77 49.6 M $264M
2026 Q1 55 30.8 M $105M
2025 Q4 48 28.5 M $82.6M
2025 Q3 47 27.2 M $39.1M
2025 Q2 51 27.2 M $22.0M
2025 Q1 59 30.5 M $26.9M
2024 Q4 63 32.2 M $41.0M
2024 Q3 71 35.8 M $74.0M
2024 Q2 62 33.9 M $129M
2024 Q1 59 34.2 M $162M
2023 Q4 57 34.7 M $148M
2023 Q3 61 36.6 M $113M
2023 Q2 56 38.5 M $176M
2023 Q1 56 31.5 M $180M
2022 Q4 61 31.2 M $188M
2022 Q3 54 31.8 M $210M
2022 Q2 63 32.7 M $171M
2022 Q1 70 34.1 M $235M
2021 Q4 79 35.2 M $438M
2021 Q3 62 36.0 M $1.12B
2021 Q2 59 34.5 M $987M
2021 Q1 61 32.5 M $1.41B
2020 Q4 52 34.7 M $2.47B
2020 Q3 40 33.3 M $1.00B